Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 11/20 | 0.87 |
| ▸ | FLT4 | P35916 | 11/20 | 0.87 |
| ▸ | KDR | P35968 | 11/20 | 0.87 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | WDR5 | P61964 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9014174 | 1.00 | FLT1 (0.87) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL10989349 | 0.93 | FLT1 (1.00) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL9176247 | 0.88 | FLT1 (1.00) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL8424044 | 0.86 | FLT1 (0.73) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL24224258 | 0.85 | FLT1 (0.84) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL9176789 | 0.85 | FLT1 (0.84) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL789891 | 0.85 | FLT1 (0.84) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL7278965 | 0.84 | P4HTM (0.65) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL7209929 | 0.83 | FLT1 (0.79) | FLT1FLT4KDRL3MBTL1PTGS1 | |
| SCHEMBL24224269 | 0.83 | FLT1 (0.79) | FLT1FLT4KDRL3MBTL1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-27 | — | — | US | disclosed |
| US-11161859-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-02 | — | — | US | disclosed |
| EP-0762887-B1 | ACYLATED ENOL DERIVATIVES AS PRODRUGS OF ELASTASE INHIBITORS | MERRELL PHARMA INC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-5972897-A | AN ANTIINFLAMMATORY AGENTS TREATING CYSTIC FIBROSIS AND EMPHYSEMA OR BOWEL DISEASES, A NEUTROPHIL ASSOCIATED INFLAMMATORY DISEASE, BRONCHITIS | MERRELL PHARMACEUTICALS INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5907068-A | TRIFLUOROMETHYLSUBSTITUTED COMPOUND INCLUDED IN PEPTIDES | ZENECA INC. (US) | 1999-05-25 | — | — | US | disclosed |
| EP-0762887-A4 | ACYLATED ENOL DERIVATIVES AS PRODRUGS OF ELASTASE INHIBITORS | MERRELL PHARMA INC (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5726158-A | INHIBITORS OF HUMAN LEUKOCYTE ELASTASE USEFUL IN TREATING TISSUE DEGENERATIVE DISEASES; TRIFLUOROMETHYL KETONE SUBSTITUTED DI-, TRI-, AND TETRA-PEPTIDE DERIVATIVES | ZENECA INC. (US) | 1998-03-10 | — | — | US | disclosed |
| US-5723442-A | OLIGOPEPTIDES AS HUMAN LEUKOCYTE ELASTASE INHIBITORS | ZENECA INC. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5698523-A | ANTIINFLAMMATORY AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1997-12-16 | — | — | US | disclosed |
| EP-0762887-A1 | ACYLATED ENOL DERIVATIVES AS PRODRUGS OF ELASTASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| US-5164371-A | HETEROCYCLIC KETONES | ICI AMERICAS INC. (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0189305-B1 | PEPTIDE DERIVATIVES | ICI AMERICAS INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| EP-0399688-A1 | Trifluoroketopeptide derivatives useful as human leukocyte elastase inhibitors | ZENECA INC. (US) | 1990-11-28 | — | — | EP | disclosed |
| EP-0397427-A1 | Fluoro-amide derivatives having human leucocyte elastase inhibiting activity | ZENECA INC. (US) | 1990-11-14 | — | — | EP | disclosed |
| EP-0369391-A2 | N-substituted amides | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4910190-A | Containing a nitrogen containing heterocycle ring structure | ICI AMERICAS INC. (US) | 1990-03-20 | — | — | US | disclosed |
| CN-1037519-A | HETEROCYCLIC KETONES | ICI AMERICA INC (US) | 1989-11-29 | — | — | CN | disclosed |
| US-4880780-A | RESPIRATORY SYSTEM DISORDERS | ICI AMERICAS INC. (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0291234-A2 | Peptidic human leukocyte elastase (HLE) inhibitors | ZENECA INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| EP-0189305-A2 | Peptide derivatives | ICI AMERICAS INC. (US) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161859-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | PCSK9, LIPA, ACSL3 | FLT1 3899/4885FLT4 3251/4885KDR 2919/4885 |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | PCSK9, PCSK7, PCSK6 | FLT1 4095/4885FLT4 3568/4885KDR 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.